Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Astellas Pharma Inc. (ALPMY : OTC)

• Company Description    Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment of atopic dermatitis in the topical immunomodulator class, Harnal to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder and Fungard an antifungal agent. Astellas Pharma, Inc. is headquartered in Tokyo, Japan. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $16.49 Daily Weekly Monthly 20 Day Moving Average: 155,294 shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 0.18 52 Week High: $16.71 52 Week Low: $8.37 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 17.12% 18.90% 12 Week 31.29% 26.81% Year To Date 24.08% 24.25%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2-5-1 Nihonbashi-Honcho Chuo-Ku - Tokyo,M0 103-8411 JPN ph: 813-3244-3000 fax: - None http://www.astellas.com

• General Corporate Information    Officers Naoki Okamura - Chief Executive Officer and President Kenji Yasukawa - Chairman of the Board Katsuyoshi Sugita - Executive Vice President Takashi Tanaka - Outside Director Tomoko Aramaki - Outside Director Peer Information Astellas Pharma Inc. (GSAC) Astellas Pharma Inc. (CASI) Astellas Pharma Inc. (ALCD.) Astellas Pharma Inc. (OMNN) Astellas Pharma Inc. (CGPI.) Astellas Pharma Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 04623U102 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 12/01/25 Next Expected EPS Date: 04/24/26 Share - Related Items Shares Outstanding: Most Recent Split Date: 4.00 (1.25:1) Beta: 0.18 Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 2.06% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.34 Current Fiscal Year EPS Consensus Estimate: $0.63 Payout Ratio: 0.24 Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: -0.24 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 04/24/26

• Fundamental Ratios P/E Current FY Estimate: 25.97 Trailing 12 Months: 11.69 PEG Ratio: - Price Ratios Price/Book: 2.99 Price/Cash Flow: 9.17 Price / Sales: - EPS Growth vs. Year Ago Period: 46.67% vs. Previous Quarter: 46.67% Sales Growth vs. Year Ago Period: 9.18% vs. Previous Quarter: 4.28% ROE 12/31/25 - 24.24 09/30/25 - 22.21 06/30/25 - 19.67 ROA 12/31/25 - 11.03 09/30/25 - 9.98 06/30/25 - 8.71 Current Ratio 12/31/25 - - 09/30/25 - 1.03 06/30/25 - 1.17 Quick Ratio 12/31/25 - - 09/30/25 - 0.80 06/30/25 - 0.89 Operating Margin 12/31/25 - 18.28 09/30/25 - 16.92 06/30/25 - 15.23 Net Margin 12/31/25 - 15.63 09/30/25 - 6.39 06/30/25 - 4.34 Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - - 06/30/25 - - Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.20 06/30/25 - 0.38 Debt-to-Capital 12/31/25 - - 09/30/25 - 16.56 06/30/25 - 27.36

Powered by Zacks Investment Research ©